DOCKING STUDY OF FLT3 RECEPTOR WITH TYROSINE KINASE FOR LEUKEMIA DISEASE

Leukemia is a disease of cancer that affects blood-forming tissues i.e., bone marrow and lymph nodes, which is associated with uncontrolled growth of WBCs. These cells are unable to fight against infection and weaken the ability of bone marrow to make RBCs and platelets. When leukemic cells overproduce, they interfere in circulatory cells’ functioning, i.e., RBCs and platelets. Along this, leukemia’s pathogenesis is unique in relation to different malignant growths which ordinarily start in major organs and then spread in bone marrow. Different types of leukemia are discovered based on different classification systems with the two major leukemia types – acute and chronic. The work includes the 50-year history of leukemia-lymphoma cell lines, which is considered a key model system in biomedicine. The work involves finding suitable protein receptors for the available potent drugs. Protein receptors are the target sites where drug molecules bind, activate and start their response. FLT3 tyrosine kinase protein is taken as a receptor to study docking concerning ligands like Abacavir, Gabapentin, etc. Autodock and Discovery Studio were used based on which best binding energy of Abacavir was found to be -7.31.